Pre-surgery treatment for high-risk rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your rectal cancer is confirmed by MRI and is close to the anal opening (within 10 cm).
- Your tumor is of the type that has normal DNA repair (pMMR or MSS/MSI-L) – your doctor will confirm this.
- Your MRI shows at least one high-risk feature, such as a large tumor (T4), or spread to lymph nodes (N2), or blood vessel involvement.
- You feel well enough to do daily activities (ECOG score 0 or 1).
- You have not had surgery, radiation, chemotherapy, or targeted therapy for this cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a combination of chemotherapy plus two newer medicines (suvemcitug and enlonstobart) before surgery for middle rectal cancer. The goal is to shrink the tumor and avoid radiation therapy, which may spare some side effects.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.